Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crispr Therapeutics Ag (NQ: CRSP )

47.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Analyst Ratings for CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
The company is using a different approach to tackle the blood disease. 
Via Investor's Business Daily
7 No-Brainer Biotech Stocks to Add to Your Buy List
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. 
Via InvestorPlace
7 Oversold Stocks to Buy Right Now
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. 
Via InvestorPlace
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize
One analyst expects multiple new drug launches between 2024-26. 
Via Investor's Business Daily
Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks
Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside. 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
Exposures Product Safety
Analyst Ratings for CRISPR Therapeutics
Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
How to Buy Stocks in a Recession
The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward. 
Via InvestorPlace
5 Cathie Wood Stocks to Buy Now
ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider. 
Via InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
Via Benzinga
$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
What 4 Analyst Ratings Have To Say About CRISPR Therapeutics
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: 
Via Benzinga
3 Cathie Wood Stocks to Count on in Q2
These Cathie Wood Stocks have their risks but offer a massive upside potential ahead, especially if you can handle the volatility. 
Via InvestorPlace
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
3 Best Stocks to Trade Right Now
Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative. 
Via InvestorPlace
Fed Rate Hike Rallies Stocks
The Federal Reserve led by Jerome Powell hiked interest rates for the first time in three years causing stocks to rally. 
Via Talk Markets
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have... 
Via Benzinga
3 Ark Invest Most-Shorted Stocks to Buy
These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers. 
Via InvestorPlace
7 Cathie Wood Stocks That Are Worth Buying in March
Many Cathie Wood stocks have suffered losses over the past year, but these companies will likely see strong gains in the coming quarters. 
Via InvestorPlace
3 Cathie Wood Stocks to Buy
Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture. 
Via InvestorPlace
Tough Slogging Ahead for Investors, Diversification is Important
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?
Savvy investors can generate lucrative returns by investing in companies that look like a number of prime takeover targets. 
Via InvestorPlace
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.